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Background:  Hypertension is common in patients with type 2 diabetes, affecting up to 60% of patients. The Korean Diabetes 
Association performed a nationwide survey about prevalence, awareness and control of hypertension among diabetic Koreans.
Methods:  The current survey included 3,859 diabetic patients recruited from 43 hospitals in Korea. Age, gender, height, weight 
and blood pressure (BP) were measured by standard methods. Data on fasting plasma glucose, glycosylated hemoglobin (HbA1c), 
awareness of hypertension, and compliance of antihypertensive medication were collected via interview and reviewed using pa-
tient medical records.
Results:  A total of 57.5% of all patients were >60 years old. Their mean HbA1c was 7.6±1.5%. Among antihypertensive medi-
cation users, 39.9% had <130 mm Hg and <80 mm Hg, whereas 60.1% had ≥130 mm Hg or ≥80 mm Hg. The answer “BP is 
under good control” was given by 75.1% of the antihypertensive medication users. Out of these patients, 26.4% had <130 mm 
Hg and <80 mm Hg, whereas 73.6% had ≥130 mm Hg or ≥80 mm Hg. A total of 75.5% of antihypertensive medication users 
answered that they had taken their antihypertensive medication every day for the past 2 weeks. “Forgetfulness” was most frequent-
ly the reason of non-compliance for patients that did not take their antihypertensive medication regularly.
Conclusion:  Approximately one third of the patients with diabetes were found to reach target blood pressure control in the 43 
hospitals across Korea. Stricter control is needed to reduce severe complications of diabetes in Korea. 
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INTRODUCTION
An epidemic of type 2 diabetes (T2DM) is a great concern in 
the Asian population [1]. Kim et al. [2] reported that the age-
adjusted prevalence of diabetes was 7.6% (men, 8.1% ; women 
7.5%). Hypertension is extremely common in patients with 
T2DM, affecting up to 60% of patients [3], consequently add-
ing significantly to its overall morbidity and mortality [4,5]. 
United Kingdom Prospective Diabetes Study (UKPDS) showed 
that strict blood pressure (BP) control in patients with hyper-
tension and T2DM achieved a clinically important reduction 
in the risk of macrovascular and microvascular complications 
in T2DM [6]. Andros et al. [7] showed that the proportion of 
patients with diabetes who had uncontrolled hypertension 
was still high and remains an important health concern ac-
counting for a large economic burden on the United States. 
Therefore, the adequate control of BP has important clinical 
and prognostic relevance in reducing economic burden in 
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subjects with type 2 diabetes.
  Recently, Lim et al. [8] reported that the prevalence of hy-
pertension among Korean diabetes was 60.4%. However, there 
is limited current epidemiologic data on the prevalence, aware-
ness and control of hypertension among diabetic Koreans. 
Here, we analyzed trends in the prevalence, awareness, treat-
ment, and control of hypertension in Korea, and determined 
whether there were further improvements in hypertension 
control according to the current treatment goals.
METHODS
Study participants
This study was a survey conducted in July to October 2010. 
The participants were diabetic patients who visited one of the 
endocrinology clinics in 43 hospitals across Korea, and had no 
mental impairments that could interfere with the survey. The 
survey was administered to a total of 3,895 participants that 
agreed to take the survey.
  The survey was approved by the independent Ethics Com-
mittee/Institutional Review Board at each study site, and writ-
ten informed consent was obtained from all participants. The 
study was performed according to the Good Clinical Practice 
Guidelines and the Declaration of Helsinki.
Clinical data collection 
The participants were interviewed individually by nurses who 
fully understood the survey questions and were trained to con-
duct the interviews. The interviewer explained the purpose of 
the survey and asked the participant for his/her consent. A 
consent form was read and signed by the participant before 
proceeding with the survey.
  The survey questionnaires were developed by an organizing 
committee representing the Korean Diabetes Association. The 
survey for patients with diabetes had 3 categories and 11 ques-
tions. Eight questions assessed general characteristics (sex, age, 
height, weight) and clinical characteristics (fasting glucose 
concentration, glycated hemoglobin level [HbA1c], treatment 
modality of diabetes, and presence of complications. A further 
3 questions pertained to the status of current hypertension 
management (awareness of target BP, compliance of antihy-
pertensive medication, type of antihypertensive medication). 
The body mass index (BMI) was calculated as the weight in ki-
lograms divided by the height in square meters. 
  Each question was delivered by an interviewer and cross-
checked with the medical records of the participant. The pur-
pose of the survey questionnaires was to identify patients ex-
periencing hypertension with diabetes awareness and their 
drug compliance. All of the information gathered from this 
survey remained confidential and was used for research pur-
poses only. 
Definition of hypertension and assessment of BP 
Hypertension was defined as systolic BP (SBP) of at least 130 
mm Hg or diastolic BP (DBP) of at least 80 mm Hg in persons 
with diabetes mellitus or self-reported use of medication for 
lowering BP [9]. Control of BP in persons with diabetes melli-
tus was defined as having a BP that was lower than 130 mm 
Hg systolic and lower than 80 mm Hg diastolic [9]. Patients 
were labeled as uncontrolled hypertension if the mean of three 
measures of SBP was ≥130 mm Hg and/or DBP was ≥80 mm 
Hg. BP was taken following recommendations of the Join Na-
tional Committee (JNC 7) [10].
  During this time two BP measures were taken in an interval 
of at least 5 minutes after patients were maintained on their 
mediation. Measurements began after 5 minutes of quiet rest 
and were made with a mercury sphygmomanometer with the 
patient seated. A cuff of suitable size was used. The SBP was 
taken at Korotkoff phase I and the DBP was taken at Korotkoff 
phase V [11]. Following that, we calculated BP as the average 
of two measurements. We also assessed the percentage of the 
entire population and those with hypertension who were uti-
lizing angiotensin-converting enzyme inhibitors (ACEIs), an-
giotensin II receptor blockers (ARBs) and other anti-hyper-
tensive medications at the time of chart review. All data are 
presented as means±standard deviation or number (%). All 
analyses were performed using SPSS version 18.0 software 
(SPSS Inc., Chicago, IL, USA).
RESULTS 
General characteristics of the survey population
Of the total 3,895 participants, 48.6% were male and 51.4% 
were female. A total of 57.5% of all patients were over 60 years 
old. The proportion of participants in their under-40s, 40s, 50s, 
60s, and over-70s were 3.7%, 10.8%, 28.2%, 32.6%, and 24.9%, 
respectively. The average BMI was 24.6±3.5 kg/m
2. Patients 
who had BMI>25 kg/m
2 represented 67.3% of the total partic-
ipants. The level of BMI decreased according to increasing age. 
Interestingly, in diabetic patients that were under 40 years old 350
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(under-40s), the proportion of BMI>30 kg/m
2 was reported as 
19.1%, and was higher than that of the other age groups (data 
not shown).
  The mean value of HbA1c was 7.6±1.5% and 58.4% of all 
participants achieved the target goal (HbA1c <7.0%) of the 
ADA guideline [9]. The mean SBP was 127.0±16.6 mm Hg, 
whereas the mean DBP was 77.0±10.6 mm Hg. In the catego-
ry of ≥130 mm Hg systolic or ≥80 mm Hg diastolic, the prev-
alence of not taking antihypertensive drugs or taking them 
was 23.8% and 37.5%, respectively (Table 1).
Awareness of target BP and control of BP
Table 2 indicates the awareness of target BP in diabetic patients. 
When asked about the awareness of target BP in diabetic pa-
tients, 62.5% of participants answered that they had known 
about their target BP. Out of all patients, the awareness of tar-
get BP in diabetic patients (≤120 mm Hg or ≤80 mm Hg) was 
47.3% and non-diabetic patients (≤130 mm Hg or ≤80 mm 
Hg) was 57.3%. 
Prevalence and compliance of antihypertensive medication 
with diabetes
Among antihypertensive medication users, 39.9% had <130 
mm Hg and <80 mm Hg whereas 60.1% had ≥130 mm Hg 
and ≥80 mm Hg. The answer “BP is under good control” was 
given by 75.1% of the antihypertensive medication users, and 
of these patients, 26.4% were in the <130 mm Hg and <80 mm 
Hg group, compared to 73.6% in the ≥130 mm Hg or ≥80 mm 
Table 1.  General characteristics of the survey participants in 
our study (n=3,895)
Characteristic Value
Age, yr
<40 140 (3.7)
40 to 50 420 (10.8)
51 to 60 1,097 (28.2)
61 to 70 1,268 (32.6)
>70 970 (24.9)
Males 1,892 (48.6)
BMI, kg/m
2 24.6±3.5
BMI>25 2,648 (67.3)
Hba1c, %  7.6±1.5
<7% of HbA1c  2,298 (58.4)
FPG 136.9±47.1
PPG  188.5±71.3
Blood pressure, mm Hg
SBP 127.0±16.6
DBP 77.0±10.6
Blood pressure goal for diabetes
<130 mm Hg and <80 mm Hg 1,508 (38.7)
 Taking a antihypertensives 792 (20.3)
 Not taking a antihypertensives 716 (18.4)
≥130 mm Hg or ≥80 mm Hg 2,387 (61.3)
 Taking a antihypertensives 1,461(37.5)
 Not taking a antihypertensives 826 (23.8)
Values are presented as mean±standard deviation or number (%).
BMI, body mass index; FPG, fasting plasma glucose; PPG, postpran-
dial 2 hour glucose; HbA1c, glycosylated hemoglobin; SBP, systolic 
blood pressure; DBP, diastolic blood pressure. 
Table 2.  Awareness of the target blood pressure in diabetic 
patients
Variable No. (%)
“I have known the target of blood  
pressure in diabetic patients.” 
Blood pressure goal for diabetes
2,436 (62.5)
 ≤120 mm Hg or ≤80 mm Hg 1,842 (47.3)
 ≤130 mm Hg or ≤80 mm Hg 2,235 (57.4)
Table 3.  Prevalence and compliance of antihypertensive med-
ication with diabetes 
Variable No. (%)
Antihypertensive medication  
Level of blood pressure 
2,253 (57.8)
 <130 mm Hg and <80 mm Hg 900 (39.9)
 ≥130 mm Hg or ≥80 mm Hg 1,353 (60.1)
“BP is under good control”  
Level of blood pressure 
1,692 (75.1)
 <130 mm Hg and <80 mm Hg 446 (26.4)
 ≥130 mm Hg or ≥80 mm Hg 1,246 (73.6)
Daily medication during recent 2 weeks
Compliance  1,611 (75.5)
Non-compliance 522 (24.5)
Reasons for non-compliance 
Forgetfulness 403 (77.3)
Drugs out of supply 20 (3.9)
Presence of drugs side effects 10 (2.0)
Absence of symptoms 8 (1.5)
Others 76 (15.3)351
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Hg group. When we analyzed compliance of antihypertensive 
medication during the past 2 weeks, 75.5% of antihypertensive 
medication users answered that they had taken antihyperten-
sive medication every day in recent 2 weeks (Table 3). Other-
wise, 24.5% were non-compliant and did not take antihyper-
tensive medication regularly. Reasons for non-compliance in-
cluded forgetfulness, drugs side effects, shortage of drugs and 
the asymptomatic nature of hypertension, and the frequency 
of each is shown in Table 3. 
Usage pattern of antihypertensive medication among 
antihypertensive medication users
The proportion of diabetic patients taking antihypertensive 
medication out of all participants was 57.8%. Antihypertensive 
medications were classified into one of six categories: ACEIs, 
ARBs, calcium channel blockers, beta-blockers, diuretics and 
alpha-blockers. A majority of antihypertensive classification 
was on angiotensin II receptor blockers 52.8%. The proportion 
of angiotensin-converting enzyme inhibitors, calcium channel 
blockers and beta-blockers was 8.9%, 21.8%, and 10.4%, re-
spectively (Table 4).
  Of patients with antihypertensive medication, the propor-
tion of monotherapy, 2 agent combinations, 3 agent combina-
tions and more than 4 agent combinations were 65.4%, 24.7%, 
7.0%, 2.9%, respectively. One third of combination therapy 
was on ARB and hydrochlorothiazide (data not shown).
DISCUSSION 
Our study is the first epidemiologic study of prevalence, 
awareness and control of hypertension among diabetic Kore-
ans. We found that the prevalence of patients that did not 
achieve target BP goal with diabetes was over 60%. These re-
sults imply that majority of type 2 diabetic hypertensive pa-
tients still do not have control of their BP. Our study also 
showed that most participants were in good control with re-
gards to BP, and of these patients, a majority were in the un-
controlled BP category. These respondents suggested that 
there was a difference between BP control in clinical practice 
and patient thoughts. Therefore, to achieve a target BP with 
diabetes, clinicians need to inform their patients of target BP, 
to reduce severe complications that may rise with diabetes in 
Korea. 
  Patient knowledge and awareness of hypertension was sig-
nificantly associated with compliance to medication for hy-
pertension. A report suggested that patients who knew about 
the importance of compliance had a significantly higher com-
pliance rate than patients who had been ignorant of that as-
pect [12]. Our study showed that there is a difference between 
antihypertensive medication compliance and BP control. Thus, 
to achieve target BP control with diabetes, clinicians should 
inform patients about the importance of target BP control.
  Controlling BP was significantly effective in reducing the 
risk of cardiovascular events and mortality in diabetic patients 
[9,13,14]. Also, current guidelines recommend lowering BP to 
<130/80 mm Hg in patients with diabetes [9,10,15,16]. There-
fore, untreated or poorly controlled hypertension in diabetic 
patients is an important health problem. The disease, patients, 
and clinician factors all contribute to poor BP control in dia-
betes [17]. However, achieving the target BP largely depends 
on patient compliance with therapy [17]. In this study, the dia-
betic patients with hypertension who did not achieve the tar-
get were more obese, younger and showed poor compliance 
with antihypertensive medication. Thus, clinicians should 
clearly distinguish these patients and establish intensive con-
trol measures. 
  The results of this study were similar with findings of other 
recently published studies [7,18,19]. These recent studies also 
found that 80% to 83% of diabetic patients with hypertension 
received drug therapy but a range of only 12% to 35% of pa-
tients controlled their BP below 130/80 mm Hg depending on 
various data sources [7,18,19]. However, in our study, about 
Table 4.  Usage pattern of antihypertensive medication among 
antihypertensive medication users
Variable No. (%)
Class of hypertensive medication 
Angiotensin II receptor blockers 1,551 (52.8)
Angiotensin-converting enzyme inhibitors 260 (8.9)
Calcium channel blockers 639 (21.8)
Beta-blockers 305 (10.4)
Diuretics 161 (5.5)
Alpha-blocker 17 (0.6)
No. of hypertension medications
Monotherapy 1,475 (65.4)
Combination therapy 780 (34.6)
2 agents 557 (24.7)
3 agents 157 (7.0)
≥4 agents 66 (2.9)352
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two-thirds of patient utilizing antihypertensive drug therapy 
still did not meet the goal for BP control, suggesting that these 
patients should be treated more rigorously to achieve controlled 
BP.
  Both ADA and JNC 7 recommended a ACEIs or ARBs as a 
first line therapy in hypertension with diabetes [9,10]. It is very 
difficult to achieve BP targets with monotherapy, and most pa-
tients require a combination of two or three drugs to get to 
target [9,10]. In combination therapy with a RAAS blocker, 
ADA suggests a low dose of a thiazide diuretic [9]. Our survey 
was consistent with these recent studies, and a majority of an-
tihypertensive medication users were on ARBs (52.8%). One-
third of combination therapy was on ARBs and hydrochloro-
thiazide (data not shown).
  The present study had some limitations. First, we used sur-
vey-based data with a limited questionnaire, resulting in the 
analysis being limited only to this particular dataset. In partic-
ular for age, this survey did not include duration of diabetes 
and exact age, but just a questionnaire for the under-40s, 40s, 
50s, 60s, and over-70s. Second, only diabetes patients who vis-
ited 43 university hospitals were selected. The characteristics 
of patients in a primary clinic may be very different from those 
in a tertiary hospital. Therefore, the results cannot be general-
ized to people with other diseases or to the general population. 
Third, although an average of up to two BP measurements were 
obtained under the same standardized conditions, there was 
the possibility of misclassification of individuals. However, the 
method of BP measurement in these surveys was consistent 
with the JNC 7 standard, which recommended the classifica-
tion of hypertension based on an average of two or more mea-
sured [20]. Fourth, participants who were in this survey were 
not randomized with enrollment.
  In conclusion, our survey found that the majority of pa-
tients with diabetes did not reach target BP control in 43 hos-
pitals across Korea. The results showed that the prevalence of 
diabetic patients with uncontrolled hypertension was still high 
and remained an important public health concern in Korea. In 
the survey results from the diabetic patients, we found that 
stricter control is needed to reduce severe complication of dia-
betes in Korea.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
ACKNOWLEDGMENTS
This study was partially supported by an unrestricted grant 
from Astrazeneca Pharmaceuticals Corporation in South Ko-
rea.
REFERENCES
1. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. 
Lancet 2010;375:408-18.
2. Kim SM, Lee JS, Lee J, Na JK, Han JH, Yoon DK, Baik SH, 
Choi DS, Choi KM. Prevalence of diabetes and impaired fast-
ing glucose in Korea: Korean National Health and Nutrition 
Survey 2001. Diabetes Care 2006;29:226-31.
3. Aubert R. Diabetes in America. 2nd ed. Bethesda: National In-
stitutes of Health, National Institute of Diabetes and Digestive 
and Kidney Disease; 1995.
4. National High Blood Pressure Education Program Working 
Group report on hypertension in diabetes. Hypertension 1994; 
23:145-58.
5. Park Y, Lee H, Koh CS, Min H, Yoo K, Kim Y, Shin Y. Preva-
lence of diabetes and IGT in Yonchon County, South Korea. 
Diabetes Care 1995;18:545-8.
6. UK Prospective Diabetes Study Group. Tight blood pressure 
control and risk of macrovascular and microvascular compli-
cations in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
7. Andros V, Egger A, Dua U. Blood pressure goal attainment ac-
cording to JNC 7 guidelines and utilization of antihypertensive 
drug therapy in MCO patients with type 1 or type 2 diabetes. J 
Manag Care Pharm 2006;12:303-9.
8. Lim S, Kim DJ, Jeong IK, Son HS, Chung CH, Koh G, Lee DH, 
Won KC, Park JH, Park TS, Ahn J, Kim J, Park KG, Ko SH, Ahn 
YB, Lee I. A nationwide survey about the current status of gly-
cemic control and complications in diabetic patients in 2006: 
The Committee of the Korean Diabetes Association on the Ep-
idemiology of Diabetes Mellitus. Korean Diabetes J 2009;33: 
48-57.
9. American Diabetes Association. Standards of medical care in 
diabetes--2011. Diabetes Care 2011;34 Suppl 1:S11-61.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green 
LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, 
Roccella EJ; National Heart, Lung, and Blood Institute Joint 
National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure; National High Blood Pres-
sure Education Program Coordinating Committee. The Sev-353
Management of blood pressure in patients with type 2 diabetes mellitus 
Diabetes Metab J 2011;35:348-353 http://e-dmj.org
enth Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure: 
the JNC 7 report. JAMA 2003;289:2560-72.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green 
LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, 
Roccella EJ; Joint National Committee on Prevention, Detec-
tion, Evaluation, and Treatment of High Blood Pressure. Na-
tional Heart, Lung, and Blood Institute; National High Blood 
Pressure Education Program Coordinating Committee. Sev-
enth report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure. 
Hypertension 2003;42:1206-52.
12. Khalil SA, Elzubier AG. Drug compliance among hypertensive 
patients in Tabuk, Saudi Arabia. J Hypertens 1997;15:561-5.
13. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull 
CA, Wright AD, Turner RC, Holman RR. Association of sys-
tolic blood pressure with macrovascular and microvascular 
complications of type 2 diabetes (UKPDS 36): prospective ob-
servational study. BMJ 2000;321:412-9.
14. Vijan S, Hayward RA. Treatment of hypertension in type 2 dia-
betes mellitus: blood pressure goals, choice of agents, and set-
ting priorities in diabetes care. Ann Intern Med 2003;138:593-
602.
15. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier 
M, Caulfield MJ, Cifkova R, Clement D, Coca A, Dominiczak 
A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty 
A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkie-
wicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, 
Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten 
PA, Viigimaa M, Zanchetti A; European Society of Hyperten-
sion. Reappraisal of European guidelines on hypertension 
management: a European Society of Hypertension Task Force 
document. J Hypertens 2009;27:2121-58.
16. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL 
Jr, Kaplan NM, O’Connor CM, O’Gara PT, Oparil S; American 
Heart Association Council for High Blood Pressure Research; 
American Heart Association Council on Clinical Cardiology; 
American Heart Association Council on Epidemiology and 
Prevention. Treatment of hypertension in the prevention and 
management of ischemic heart disease: a scientific statement 
from the American Heart Association Council for High Blood 
Pressure Research and the Councils on Clinical Cardiology and 
Epidemiology and Prevention. Circulation 2007;115:2761-88.
17. Wang TJ, Vasan RS. Epidemiology of uncontrolled hyperten-
sion in the United States. Circulation 2005;112:1651-62.
18. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, 
awareness, treatment, and control of hypertension among 
United States adults 1999-2004. Hypertension 2007;49:69-75.
19. Wong ND, Lopez VA, L’Italien G, Chen R, Kline SE, Franklin 
SS. Inadequate control of hypertension in US adults with car-
diovascular disease comorbidities in 2003-2004. Arch Intern 
Med 2007;167:2431-6.
20. Chaturvedi S. The Seventh Report of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure (JNC 7): is it really practical? Natl Med J 
India 2004;17:227.